High Dose Chemotherapy With Melphalan and Autologous Stem Cell Transplantation (HDM-ASCT) | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Patient Education

High Dose Chemotherapy With Melphalan and Autologous Stem Cell Transplantation (HDM-ASCT)

key information

source: University College London

year: N/A

summary/abstract:

AL amyloidosis is caused by the abnormal proteins, called free light chains, which are produced by abnormal cells, called monoclonal plasma cells, in the bone marrow. The chemotherapy treatment given to all AL patients is aimed at killing these abnormal cells and thereby eliminating the free light chains, which form the AL amyloid deposits in the tissues and organs. When this is achieved, the patient is said to have had a ‘complete response’. 

In such patients, no new amyloid forms for as long as the response persists and existing amyloid deposits may slowly go away in many individuals, while organ function and clinical wellbeing improve and are maintained. Unfortunately all the chemotherapy drugs damage normal cells in the bone marrow and elsewhere, as well as the abnormal cells which produce the amyloid forming free light chains. This is why chemotherapy has so many adverse side effects. 

The toxicity of chemotherapy limits the doses that can be safely given and thus its effectiveness. Many patients cannot tolerate enough treatment to obtain a complete remission and thus the best possible outcome.

 

read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close